LYMPHIR
Growthdenileukin diftitox-cxdl
BLAINJECTIONINJECTABLE
Approved
Aug 2024
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
3/8 — Basic
LYMPHIR (denileukin diftitox-cxdl) is diftitox-cxdl is a fusion protein designed to direct the cytocidal action of diphtheria toxin (dt) to cells which express the il-2 receptor. First approved in 2024.
Drug data last refreshed 17h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LYMPHIR (denileukin diftitox-cxdl) is a CD25-directed cytotoxin fusion protein combining diphtheria toxin with IL-2 receptor targeting. It works by binding to IL-2 receptor-expressing cells, undergoing cellular uptake, and inducing protein synthesis inhibition and cell death. The drug depletes immunosuppressive regulatory T lymphocytes (Tregs) and demonstrates direct cytocidal activity against IL-2R-expressing tumors.
Growth
Newly approved product in growth phase signals emerging commercial infrastructure build and potential team expansion opportunities across sales, marketing, and medical affairs.
Mechanism of Action
diftitox-cxdl is a fusion protein designed to direct the cytocidal action of diphtheria toxin (DT) to cells which express the IL-2 receptor. After uptake into the cell, the DT fragment is cleaved and the free DT fragments inhibit protein synthesis, resulting in cell death. Denileukin diftitox-cxdl…
Pharmacologic Class:
CD25-directed Cytotoxin
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on LYMPHIR at launch offers high-visibility exposure to a novel immuno-oncology mechanism in a growth-stage product with undefined peak potential. Early-career professionals can build expertise in a first-in-class-or-best-in-class franchise with strong scientific differentiation and opportunities to shape market positioning.
Brand Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.